Tonix Pharmaceuticals Holding Corp. (TNXP): restructuring charge — Tonix cuts 23 employees, closes Mass. facility; shareholders approve reverse stock split

Tonix Pharmaceuticals Holding Corp.

Workforce reduction of 23 FTEs and decommissioning of Advanced Development Center in Mass. by June 7, 2024.
No material charge expected for restructuring; impairment amount not yet determinable.
Shareholders (61.6% of shares) elected 8 directors, ratified EisnerAmper as auditor.
Approved reverse stock split of 1:2 to 1:50, board to set exact ratio within one year.
Approved repricing of up to 93.4M warrants issued Aug-Dec 2023.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Tonix Pharmaceuticals Holding Corp. announced a restructuring affecting Advanced Development Center ("ADC") in Massachusetts (23 full-time employees).

Type: restructuring
Affected area: Advanced Development Center ("ADC") in Massachusetts
Headcount: 23 full-time employees

Exact text from the filing

Tonix Pharmaceuticals Holding Corp. (the “Company”) plans to reduce its workforce by 23 full-time employees and decommission its Advanced Development Center (“ADC”) in Massachusetts by June 7, 2024, to align the Company’s capital and human resources with its previously announced strategic prioritization of its TonmyaTM (TNX-102 SL cyclobenzaprine HCl sublingual tablet) product candidate for the management of fibromyalgia

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-24-006472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.